Intech Biopharm

Intech Biopharm EPS Growth

The EPS Growth of Intech Biopharm (6461.TWO) as of Nov 18, 2026 is -5.66 %. In the previous year, EPS Growth was -2.63 % — a change of 114.65% (lower).

EPS Growth

-5.66 %

YoY

114.65%

Last updated:

EPS Growth of Intech Biopharm is 2025 -5.66 % . EPS Growth of Intech Biopharm was 2024 -2.63 % . It decreases by 114.65% lower compared to the previous year.

The Intech Biopharm EPS Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS Growth
Date
EPS Growth
Jan 1, 2018
7.20 TWD
Jan 1, 2019
-40.23 TWD
Jan 1, 2020
-8.72 TWD
Jan 1, 2021
-4.40 TWD
Jan 1, 2022
-8.03 TWD
Jan 1, 2023
6.05 TWD
Jan 1, 2024
-2.63 TWD
Jan 1, 2025
-5.66 TWD
The Intech Biopharm EPS Growth history
YEAREPS GrowthYoY
-5.66 %+114.65%
-2.63 %-143.58%
6.05 %-175.34%
-8.03 %+82.33%
-4.40 %-49.49%
-8.72 %-78.34%
-40.23 %-658.53%
7.20 %+145.92%
2.93 %-21.33%
3.72 %-109.00%
-41.35 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Intech Biopharm Stock analysis

What does Intech Biopharm do? Intech Biopharm Ltd is a pharmaceutical company based in Taipei City, Taiwan. The company went public on July 15, 2014, with the ticker symbol 6461.TWO and ISIN TW0006461007. It operates within the Health Care sector, specifically in the Pharmaceuticals industry. Intech Biopharm focuses on developing drugs for obstructive airway diseases, including bronchial asthma and chronic obstructive pulmonary disease. The company's primary products are respiratory drugs, notably the Duasma hexafluoroacetone (HFA) metered-dose inhalers (MDIs) and the Synvent HFA MDIs. These products are distributed both domestically within Taiwan and internationally. The company maintains a website at http://www.intechbiopharm.com/ for further information. Intech Biopharm Ltd is engaged in the research, development, and distribution of pharmaceutical products targeting respiratory conditions, with a focus on innovative inhaler technologies. The firm's operations are centered on addressing unmet medical needs in respiratory care through its specialized drug formulations. Intech Biopharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Intech Biopharm stock

EPS Growth of Intech Biopharm is -5.66 % in 2025.

On Eulerpool you can find the complete historical development of EPS Growth Intech Biopharm since 2006 – with annual values, charts, and detailed analysis.

EPS growth measures the percentage change in earnings per share. It accounts for both profit changes and share count changes.

To evaluate EPS Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EPS Growth.

EPS Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EPS Growth's Intech Biopharm historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Intech Biopharm

All Key Metrics — Intech Biopharm